Triumph

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada

Retrieved on: 
Friday, October 28, 2022
Heartburn, Birth, Gastroesophageal reflux disease, Health, Triumph, GERD, Safety, Oval Office Operations, Gastrointestinal disease, CEO, Medication, Risk, Intrauterine device, PPI, Food, Inflammation, Plasma protein binding, Patient, HK, Maintenance, US Foods, NERD, Esophagus, Partnership, Colonoscopy, Gastroenterology, Enzyme inhibitor, Marketing, FDA, GI, Time, Esophageal cancer, N, Pharmaceutical industry

BRAINTREE, Mass., Oct. 28, 2022 /PRNewswire/ -- Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada. Under the agreement, Braintree Laboratories, a leader in gastroenterology and an affiliate of Sebela Pharmaceuticals, will be responsible for clinical development, registration, marketing, and sales in the United States and Canada. Tegoprazan, a novel potassium-competitive acid-blocker (P-CAB), is currently approved and marketed in several territories, including South Korea and China. 

Key Points: 
  • BRAINTREE, Mass., Oct. 28, 2022 /PRNewswire/ --Sebela Pharmaceuticals has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada.
  • "We are delighted to add tegoprazan to our product pipeline," said Alan Cooke, President and CEO of Sebela Pharmaceuticals.
  • "We are delighted to partner with Sebela Pharmaceuticals," Dal-Won Kwak, CEO, HK inno.N said in a statement.
  • We believe Sebela Pharmaceuticals is the ideal partner to develop and commercialize tegoprazan in the United States and Canada."

Triumph Mountain Properties Announces The Apex Collection

Retrieved on: 
Wednesday, October 26, 2022
Opus, Apex, Growth, Transport, Collection, Technology, Hotel, Ethos, Triumph

VAIL, Colo., Oct. 26, 2022 /PRNewswire/ -- Triumph Mountain Properties announces the launch of The Apex Collection, an ultra-luxury portfolio of Vail Valley short term rental properties. The collection is anchored by a spectacular $60 million duo of interconnected homes, Ethos and Opus located at 99-100 Vail Road, available for vacation rentals for the first time ever, offered exclusively by Triumph Mountain Properties. The new collection launches with a total of five luxury estates whose aggregate value is nearly $100,000,000.

Key Points: 
  • VAIL, Colo., Oct. 26, 2022 /PRNewswire/ -- Triumph Mountain Properties announces the launch of The Apex Collection , an ultra-luxury portfolio of Vail Valley short term rental properties.
  • With deep roots in the Vail Valley, Triumph Mountain Properties has managed upscale short term rentals in the Vail and Beaver Creek areas for more than twenty years.
  • Apex by Triumph Mountain properties is the culmination of its longstand Vail Valley hospitality legacy, its portfolio growth in the luxury space, and the longstanding trust high value homeowners have placed in Triumph, along with its general manager, Michael Connolly.
  • Introducing the apex of luxury in the Vail Valley: The culmination of over twenty years of celebrated hospitality standards, Apex by Triumph Mountain Properties is a new and boutique collection rising out of our portfolio as the pinnacle of ultra-luxury Vail Valley vacation rentals.

Triumph Bancorp Releases Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, October 19, 2022
International, U.S. Securities and Exchange Commission, CFO, Triumph, Investor relations, Security (finance), Baozou Big News Events, Nasdaq, Company, CEO, TBK, Letter, GLOBE, News, Webcast, Forward-looking statement, ID, Video game, Risk management

DALLAS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Triumph Bancorp, Inc. (Nasdaq: TBK) has released its third quarter 2022 financial results.

Key Points: 
  • DALLAS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Triumph Bancorp, Inc. (Nasdaq: TBK) has released its third quarter 2022 financial results.
  • The Q3 2022 financial results and shareholder letter are available on the investor relations section of the Companys website at ir.triumphbancorp.com through the News & Events, Webcasts & Presentations links.
  • Aaron P. Graft, Vice Chairman and CEO, and Brad Voss, CFO, will review the financial results in a conference call with investors and analysts beginning at 7:00 a.m. CT on Thursday, October 20, 2022.
  • Triumph Bancorp, Inc. (Nasdaq: TBK) is a financial holding company headquartered in Dallas, Texas, offering a diversified line of payments, factoring, and banking services.

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada

Retrieved on: 
Wednesday, October 19, 2022
Time, Birth, Risk, US Foods, Health, Patient, PPI, Gastrointestinal disease, HK, Gastroenterology, Colonoscopy, Multimedia, Esophageal cancer, Enzyme inhibitor, Inflammation, GI, Intrauterine device, Partnership, Food, Plasma protein binding, Oval Office Operations, N, Marketing, CEO, Safety, GERD, Triumph, Medication, Maintenance, Gastroesophageal reflux disease, Heartburn, FDA, Esophagus, NERD, Pharmaceutical industry

BRAINTREE, Mass., Oct. 19, 2022 /PRNewswire/ -- Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada. Under the agreement, Braintree Laboratories, a leader in gastroenterology and an affiliate of Sebela Pharmaceuticals, will be responsible for clinical development, registration, marketing, and sales in the United States and Canada. Tegoprazan, a novel potassium-competitive acid-blocker (P-CAB), is currently approved and marketed in several territories, including South Korea and China. 

Key Points: 
  • BRAINTREE, Mass., Oct. 19, 2022 /PRNewswire/ --Sebela Pharmaceuticals has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada.
  • "We are delighted to add tegoprazan to our product pipeline," said Alan Cooke, President and CEO of Sebela Pharmaceuticals.
  • "We are delighted to partner with Sebela Pharmaceuticals," Dal-Won Kwak, CEO, HK inno.N said in a statement.
  • We believe Sebela Pharmaceuticals is the ideal partner to develop and commercialize tegoprazan in the United States and Canada."

Triumph Bancorp Announces Schedule for Third Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Saturday, October 8, 2022
International, U.S. Securities and Exchange Commission, CFO, Triumph, Investor relations, Security (finance), Nasdaq, USCT, Company, CEO, TBK, Baozou Big News Events, File, GLOBE, News, Webcast, Forward-looking statement, ID

DALLAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Triumph Bancorp, Inc. (Nasdaq: TBK) today announced that it expects to release its third quarter financial results and management commentary after the market closes on Wednesday, October 19, 2022.

Key Points: 
  • DALLAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Triumph Bancorp, Inc. (Nasdaq: TBK) today announced that it expects to release its third quarter financial results and management commentary after the market closes on Wednesday, October 19, 2022.
  • Alternatively, a live conference call option is available by dialing 1-800-267-6316 (International: +1-203-518-9765) requesting to be joined to conference ID Triumph at the operator prompt.
  • Triumph Bancorp, Inc. (Nasdaq: TBK) is a financial holding company headquartered in Dallas, Texas, offering a diversified line of payments, factoring, and banking services.
  • Forward-looking statements speak only as of the date made and Triumph undertakes no duty to update the information.

Fresh off $46m Fund Raise, N3TWORK Studios Unveils Web3 RPG Legendary: Heroes Unchained

Retrieved on: 
Wednesday, October 5, 2022
Technology, Electronic Games, NFT, Entertainment, Professional Services, Software, Blockchain, Internet, Consumer Electronics, Web3, Sale, Triumph, Edition, EA, NFT, LHU, Collection, Activision, Marvel, Blockchain, Founder, Double Fine, RPG, Zynga, Video game, The Walt Disney Company, Discord

Fresh off the announcement of a $46M funding round, Web3 games company N3TWORK Studios has unveiled RPG hero collector Legendary: Heroes Unchained (LHU).

Key Points: 
  • Fresh off the announcement of a $46M funding round, Web3 games company N3TWORK Studios has unveiled RPG hero collector Legendary: Heroes Unchained (LHU).
  • This new entry into the smash hit Legendary universe will take familiar heroes and gorgeous art from the world of Korelis and use it to redefine fun in the world of Web3 gaming.
  • N3TWORK Studios is a newly formed gaming studio whose mission is to create incredible experiences in, on, and around the blockchain.
  • N3TWORK Studios is working on a diverse portfolio of multiplatform titles, including Legendary Heroes Unchained and Triumph.

TriumphPay Appoints Dan Curtis as EVP, Chief Relationship Management Officer

Retrieved on: 
Monday, October 3, 2022
Â, BNSF, TBK, Technology, FDIC, Nasdaq, Industry, U.S. Securities and Exchange Commission, Ernst & Young, Triumph, LLC, Leadership, Security (finance), OTR, Forward-looking statement, Tate, SSB, Hicks, GLOBE, HM Capital Partners, Management

DALLAS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- TriumphPay, a division of TBK Bank, SSB, today announced the appointment of Dan Curtis as executive vice president, chief relationship management officer.

Key Points: 
  • DALLAS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- TriumphPay, a division of TBK Bank, SSB, today announced the appointment of Dan Curtis as executive vice president, chief relationship management officer.
  • In this role, Curtis will provide strategic leadership for TriumphPays client relationship team, as well as identify key business drivers for clients and ensure TriumphPay is meeting client demands.
  • Were incredibly excited to have Dan join our team, said Aaron P. Graft, vice chairman and chief executive officer of Triumph Bancorp, Inc. (Nasdaq: TBK).
  • Before taking over the role of president of BNSF Logistics in 2018, he served as the chief operating officer and chief financial officer for BNSF Logistics for seven years.

NAVSUP AWARDS TRIUMPH SPARE UNITS ON V-22 PLATFORM

Retrieved on: 
Thursday, September 22, 2022
Triumph, PCA, United States Navy, Bell Boeing V-22 Osprey, NAVSUP, NYSE, V-22, Housing

BERWYN, Pa., Sept. 22, 2022 /PRNewswire/ -- Triumph Group, Inc., (TRIUMPH) (NYSE: TGI)and NAVSUP have entered into an agreement to provide Pylon Conversion Actuators (PCA) spare units for the V-22 Osprey, a U.S. Navy tiltrotor military aircraft.

Key Points: 
  • BERWYN, Pa., Sept. 22, 2022 /PRNewswire/ -- Triumph Group, Inc., (TRIUMPH) (NYSE: TGI)and NAVSUP have entered into an agreement to provide Pylon Conversion Actuators (PCA) spare units for the V-22 Osprey, a U.S. Navy tiltrotor military aircraft.
  • The V-22 Osprey combines the functionality of a helicopter and the long-range and speed of a turboprop aircraft.
  • The units will be designed and manufactured at TRIUMPH Geared Solutions in Park City, Utah.
  • "TRIUMPH provides substantial content on the V-22 aircraft, including the PCA, a product that enables the aircraft to convert from helicopter to airplane mode," said Pete Gibson, President of TRIUMPH Geared Solutions.

Triumph Orthopedics Announces Its First Practice Partnership With Georgia Bone & Joint Surgeons, P.C.

Retrieved on: 
Monday, September 19, 2022
Health, Practice Management, Physical Therapy, Other Health, Real estate, Food, Inc. (magazine), Elective surgery, Association, Health, Growth, Partnership, P.C, Industry, GB, Patient, Investment, Physician, CEO, Brad, Goal, Corporate services, Triumph, Research, Medicine, Health care, Human, Multimedia, Pitch, Tutoring, Hospital, Management, Dentistry, DRS, Health, Practice Management, Physical Therapy, Other Health

2838249 Triumph Orthopedic Partners (Triumph) is pleased to announce it has entered a partnership with Georgia Bone and Joint Surgeons, P.C.

Key Points: 
  • 2838249 Triumph Orthopedic Partners (Triumph) is pleased to announce it has entered a partnership with Georgia Bone and Joint Surgeons, P.C.
  • (Georgia Bone and Joint or GB&J or the Practice).
  • Georgia Bone and Joint is a leading orthopedics practice in northwest Georgia that is comprised of the physician team of Drs.
  • Triumph is thrilled to establish our presence in the state of Georgia by collaborating with such a strong partner in GB&J.

Kanfit Increased Material Yield with Plataine's AI and IIoT Based Optimization Software

Retrieved on: 
Wednesday, September 7, 2022
Composite, CEO, Triumph, Program, Airbus, ERP, Future, AMRC, IAI, Solution, SAP, Industry, Industrial, NCC, ST Engineering, SME, Frost & Sullivan, CNC, Bell Textron, GE, Compliance, Personal digital assistant, Siemens PLM Software, IFS, MRAS, Israel Aerospace Industries, The Economist, Automation, JEC, Frost, CTC, AI, Industrial internet of things, Efficiency, Ministry of Education (Malaysia), Recycling, 3D printing, Boeing

WALTHAM, Mass., Sept. 7, 2022 /PRNewswire-PRWeb/ -- Kanfit, a leading manufacturer of parts and assemblies for aerospace, medical devices, and other industries—that deliver ready-to-fly assemblies and products made of composites and advanced metals—reveals how it benefits from Plataine's AI and IIoT based optimization solution by automating and streamlining its raw material tracking, management, and planning, to significantly reducing waste and production delays.

Key Points: 
  • Kanfit managed to address these challenges with Plataine's optimization solution, due to its strong experience in implementing Industry 4.0 solutions in the aerospace industry.
  • Plataine's Time sensitive Material Management (TSMM) solution prevents usage of expired material or material likely to expire by the time the work order is completed.
  • With Plataine's TSMM solution, material information is automatically collected from factory sensors and logged throughout the entire manufacturing process, eliminating manual reporting and paperwork.
  • The digitized and automated solution contributes to factory-wide benefits, improving overall efficiency, minimizing rework and waste, increasing material yield and ensuring compliance with audits.